UK markets close in 8 hours 28 minutes

Merck & Co., Inc. (MRK)

NYSE - NYSE Delayed price. Currency in USD
Add to watchlist
129.22-0.90 (-0.69%)
At close: 04:00PM EDT
129.55 +0.33 (+0.26%)
After hours: 07:52PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close130.12
Open131.72
Bid0.00 x 800
Ask0.00 x 900
Day's range128.98 - 130.92
52-week range99.14 - 133.10
Volume6,798,214
Avg. volume8,287,572
Market cap327.318B
Beta (5Y monthly)0.40
PE ratio (TTM)143.58
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yield3.08 (2.38%)
Ex-dividend date14 Mar 2024
1y target estN/A
  • Insider Monkey

    Merck & Co., Inc. (NYSE:MRK) Q1 2024 Earnings Call Transcript

    Merck & Co., Inc. (NYSE:MRK) Q1 2024 Earnings Call Transcript April 25, 2024 Merck & Co., Inc. beats earnings expectations. Reported EPS is $2.07, expectations were $1.94. Merck & Co., Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Thank […]

  • Simply Wall St.

    Merck & Co., Inc. (NYSE:MRK) Just Released Its First-Quarter Earnings: Here's What Analysts Think

    Merck & Co., Inc. ( NYSE:MRK ) just released its quarterly report and things are looking bullish. The company beat...

  • Benzinga

    Merck Stock Gains On Its Blockbuster Cancer Drug Keytruda, Raises Annual Outlook

    On Thursday, U.S. drug maker Merck & Co Inc (NYSE:MRK) reported first-quarter sales of $15.8 billion, up 9% year-over-year, beating the consensus estimate of $15.2 billion. Excluding the impact of foreign exchange, sales increased 24%. Merck reported adjusted EPS of $2.07, up 48%Y/Y, beating the consensus of $1.88. Merck’s pharmaceutical unit booked $14.01 billion in revenue during the first quarter, up 10% Y/Y. Related: Merck’s $11B Bet Pays As FDA Approves Sotatercept For Rare Lung Disease. Me